Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4751–4800 of 76300
interim CFO Alissa Vickery will return to her full-time role as Chief Accounting Officer.
the Board of Directors appointed Michael Howe, currently a member of the Board of Directors, to serve as Chief Executive Officer of the Company, effective June 10, 2025.
On June 10, 2025, Kraig Higginson, Chief Executive Officer of Aspire Biopharma Holdings, Inc. (the “Company”), notified the Board of Directors of his intention to step down from the role of Chief Executive Officer, effective June 10, 2025.
the board of directors of the Company has appointed Mr. Guojian Chen as Chief Executive Officer of the Company, effective June 10, 2025.
Mr. Shaoke Li recently tendered to the board of directors his resignation from the positions of Chief Executive Officer and Director of DT Cloud Acquisition Corporation (the “Company”), effective June 10, 2025.
terminated the employment of David Beers, its Chief Financial Officer without cause
appointed Joseph DosSantos, its current Senior Vice President Finance, as the Company's interim CFO while the Company conducts a search for a new CFO.
Mr. Larkins resigned as a director of the Company effective June 9, 2025.
On June 10, 2025, Safehold Inc., our external manager, announced it has appointed Christopher Uhlick, as its Chief Accounting Officer effective July 7, 2025 (the “Effective Date”).
As of the Effective Date, Mr. Uhlick will also serve as Star Holdings’ (the “Company”) Chief Accounting Officer and succeed Brett Asnas as principal accounting officer.
On June 9, 2025, the Board of Directors of The Procter & Gamble Company (the “Company”) appointed Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, as a Director of the Company, effective June 9.
On June 6, 2025, Andrew J. Namenye, Executive Vice President, Chief Legal and HR Officer, and Corporate Secretary of LCI Industries (the “Company”), notified the Company of his intention to voluntarily resign from the Company.
Andrew C. Warren, the Company’s Strategic Advisor to the Office of the CEO, will assume the additional duties of Executive Vice President, Interim Chief Financial Officer and principal financial officer of the Company after the departure of Mr. Chopra.
On June 3, 2025, Naveen Chopra, the Executive Vice President, Chief Financial Officer of Paramount Global (the “Company”), notified the Company of his decision to resign from his position, effective June 27, 2025.
Mr. Snyder is succeeding Mr. Thomas Amato, the current President and Chief Executive Officer of the Company.
The Board also has appointed Mr. Snyder as a member of the Board, effective June 23, 2025
appointed Mr. Thomas Snyder to the position of President and Chief Executive Officer of the Company (" CEO "), effective as of June 23, 2025
Daniel Cunha will become Chief Financial Officer of the Company, effective July 1, 2025.
On June 4, 2025, Aoife Brennan, M.B., B.Ch. provided to the Board of Directors (the “Board”) notification of her resignation from the Board of FibroGen, effective June 4, 2025.
Effective June 4, 2025, the Board of the Company, upon recommendation of the Nominating and Corporate Governance Committee, appointed Michael Kauffman, M.D., Ph.D. as a Class III director of the Company.
John Sculley notified the Board of his decision to retire as a director of the Board, effective immediately.
Effective June 5, 2025, the Company's Chair, John S. Moody, retired as Chair of the Board and Douglas B. Hansen assumed the position of the Company's Chair of the Board.
Effective June 5, 2025, the Company's Chair, John S. Moody, retired as Chair of the Board and Douglas B. Hansen assumed the position of the Company's Chair of the Board.
On June 5, 2025, the Board of Directors appointed Jeanette M. Bjorkquist to serve as the Company’s principal financial officer in addition to her role as principal accounting officer.
Ms. Bjorkquist succeeds Jason A. Okazaki, who previously served as both the Company’s principal executive officer and principal financial officer.
Effective June 6, 2025, the Board of Directors (the “Board”) of the Company increased the number of directors to five and appointed Messrs. Shawn Canter and Aron Schwartz to serve as members of the board of directors of the Company.
Effective June 6, 2025, the Board of Directors (the “Board”) of the Company increased the number of directors to five and appointed Messrs. Shawn Canter and Aron Schwartz to serve as members of the board of directors of the Company.
Effective as of the Separation Date, the Board appointed Tammy Furlong, age 54, the Company’s Chief Financial Officer and Principal Financial and Accounting Officer, to succeed Mr. Ferra as President and Interim Chief Executive Officer
In connection with the Merger, the Company terminated the employment of Joseph J. Ferra, Jr., as the Company’s President, Chief Executive Officer, effective as of June 30, 2025
On June 8, 2025, Dr. Alan J. Tuchman resigned as Chief Executive Officer and director of the Company, effective June 8, 2025. Dr. Tuchman will serve as Chief Medical Officer of the Company.
On June 4, 2025, Dr. Daniel L. Alkon resigned as an officer, director and Chief Science Officer of the Company to become a consultant working with the Company’s newly established Bryostatin Development Committee
On June 6, 2025, Mr. Joshua Silverman was appointed as Executive Chairman of the Company’s board of directors and in consideration of his new role, Mr. Silverman will be paid a monthly salary of $30,000 per month.
Mr. Moss will serve as a Class I Director, with a term expiring at the Company's 2025 annual meeting of stockholders and will serve on the Nominating and Corporate Governance Committee of the Board.
Mr. Roberts will serve as a Class III Director, with a term expiring at the Company’s 2027 annual meeting of stockholders and will serve on the Audit and Risk Committee and the Compensation Committee of the Board.
On June 9, 2025, International Flavors & Fragrances Inc. (the “Company”) announced that Ms. Virginia Drosos has been appointed to its board of directors (the “Board”), effective June 16, 2025 (the “Effective Date”).
the Board increased the size of the Board by one to a total of eight Directors and appointed Corning Painter as a Director, effective immediately.
Ken Moelis, who has served as Chief Executive Officer of the Company since the Company’s inception in 2007, will become Executive Chairman.
Jeff Raich, Co-Founder and Co-President, has been appointed Executive Vice Chairman of Moelis and will continue to lead key business areas of the Firm.
Navid Mahmoodzadegan, Co-Founder and Co-President, will succeed Mr. Moelis as Chief Executive Officer and will also join the Board of Directors of the Company.
Mr. Martin resigned from the Board
Mr. Brust was appointed as a member of the Board
Scott Behrens will cease to serve as Executive Vice President, Chief Financial Officer and Chief Accounting Officer of the Company effective July 1, 2025.
On June 9, 2025, ACI Worldwide, Inc. (the “Company”) announced the appointment of Robert Leibrock as its Chief Financial Officer and Chief Accounting Officer effective July 1, 2025.
On June 4, 2025, General Dynamics Corporation (the “company”) announced that Danny Deep, currently executive vice president, Combat Systems, has been promoted to executive vice president, Global Operations.
On June 9, 2025, Symbotic Inc. (the “Company”) announced the appointment of Izilda “Izzy” Martins as Chief Financial Officer and principal financial officer of the Company, effective August 9, 2025.
on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.
Richard Matricaria, formerly the Company’s Chief Operating Officer, Western Division, was named Senior Vice President and Chief Growth Officer effective May 1, 2025.
Randy Breaux will be retiring as Group President, GPC North America, effective as of August 1, 2025
the Board of Directors of the Company has appointed Alain Masse to the newly created position of President, North American Automotive, effective as of the Effective Date.
On June 5, 2025, the Board of Directors (the “Board”) of biote Corp. (the “Company”), following the recommendation of the Nominating and Corporate Governance Committee, appointed Richard R. Barrera to serve as a member of the Board to fill the vacancy created by the prior resignation of Steven J. Heyer
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.